3 ms·
For the particular indication we were going after there had been a number of topical trials and academic studies that showed that the placebo response was less
by gumby 5y ago
For the particular indication we were going after there had been a number of topical trials and academic studies that showed that the placebo response was less than 1%, essentially no different from spontaneous (i.e. no treatment). Same was true of oral. This is pretty common in fungal infections unfortunately.
The FDA wanted us to compare against the topical treatment placebo rate for various technical reasons.
Perhaps you thought that “standard” was some sort of standard for any placebo for any indication and any mode of administration? Indeed that would make no sense.
Even specifying a placebo itself is non obvious. Of course your procedure and the object itself (tablet, whatever) is ideally indistinguishable by the study participant and, ideally the clinician (hard to do, say, when it’s a surgical procedure; you can’t hide that from the clinician). But even with a pill, you can’t always just supply, say, a slug of mannitol — that might actually affect what you’re studying.
- civilized 5y agoThanks, this is helpful additional info. Sorry, I didn't mean to contradict you, I was actually trying to reinforce the principle behind your experience. There is no true "standard" for what sort of placebo should be used in a trial, even if something has become "standard" in the sense of commonly used. It is not something that can be specified in the abstract, but is a matter of expert judgment with many variables. Your trial gave an appropriate placebo, regardless of the "standard" in the field, and thus you were shielded from overstating the evidence of drug effectiveness.